BCDA - Biocardia Inc logo

Biocardia Inc

BCDA

BioCardia develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its key products include CardiAMP, a cell therapy for ischemic heart failure, and CardiALLO and PulmALLO, both targeting heart and respiratory conditions.

⚕️ Healthcare NASDAQ Listed 2008 $ USD
$1,000 invested 20 years ago →$1today

Score Overview

1 Year
Score—
Net Growth10.80%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score5.1
Net Growth41.85%
Net Trend80%
Net Income Consistency—
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency—
10 Years
Score
Net Growth28.82%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-26.53%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend63%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Biocardia Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • BCDA

2019: 96.1% · 2020: 94.6% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.93—
1 Year2025-10-22
$ 1.46-36.39%
5 Years2021-10-22
$ 42.30-97.80%
10 Years2016-10-21
$ 178.20-99.48%
20 Years2006-10-18
$ 1.13K-99.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 7M$ 4M
2025$ 0.00-$ 8M$ 2M
2024$ 58K-$ 7M$ 2M
2023$ 477K-$ 11M$ 1M
2022$ 1M-$ 11M$ 7M
2021$ 1M-$ 12M$ 12M
2020$ 145K-$ 15M$ 21M
2019$ 710K-$ 14M$ 5M
2018$ 625K-$ 13M$ 5M
2017$ 479K-$ 12M$ 12M
2016$ 576K-$ 10M$ 21M
2015$ 517K$ 322K$ 13M
2014$ 427K$ 234K$ 13M
2013$ 268K$ 13M
2012$ 62K$ 305K$ 13M
2011$ 12K$ 9M$ 12M
2010-$ 11M$ 127K
2009$ 1M-$ 5M$ 4M
IPO2008$ 1M-$ 5M$ 3M
BCDA - Biocardia Inc logo

Biocardia Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 145K to $ 0.00 and net income went from -$ 15M to -$ 8M. Revenue increased in 1 of those 5 years; net income in 4.

Across Biocardia Inc's full reported history, from 2008 to 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 5M to -$ 8M. Revenue increased in 63% of the years measured; net income in 50%.

Biocardia Inc currently holds a 5-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.

Membership

Continue BCDA’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies